Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes to Treat Severe Chronic Heart Failure

NCT05566600 is registered in ClinicalTrials.gov with HELP Therapeutics Co., Ltd. as lead sponsor.

NCT NCT05566600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05566600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes to Treat Severe Chronic Heart Failure
Lead sponsor
HELP Therapeutics Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
October 9, 2022
Completion date
July 31, 2025
Enrollment
32 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure, ischemic heart failure